์ธํํฐ์คํผ ์ผ์ฐ์ผ
์ธํํฐ์คํผ ์ผ์ฐ์ผ(Ceftiofur HCl)์ **์์ํ ์ ์ฉ 3์ธ๋ ์ธํ๋ก์คํฌ๋ฆฐ** ํญ์์ ์ ๋๋ค. ์ฃผ๋ก ๋๋๋ฌผ(ํนํ ๋ผ์ง์ ์)์ ์ธ๊ท ์ฑ ํธํก๊ธฐ ์งํ, ๋ถ์ ๋ณ, ๊ธ์ฑ ์๊ถ๋ด๋ง์ผ ๋ฐ ์ ๋ฐฉ์ผ ์น๋ฃ์ ์ฌ์ฉ๋ฉ๋๋ค. ์ฃผ์ ํน์ง: * **๊ด๋ฒ์ ํญ๊ท ๋ ฅ:** *ํ์คํด๋ ๋ผ*, *์ฐ์์๊ตฌ๊ท *, *ํฌ๋์๊ตฌ๊ท *, *์ด๋ชจ๋ฌ๋ผ*, *๋์ฅ๊ท *์ ํฌํจํ ๋ค์ํ ๊ทธ๋ ์์ฑ ๋ฐ ์์ฑ ๋ณ์๊ท ์ ํจ๊ณผ์ ์ ๋๋ค. * **ํ์ฑ ๋์ฌ์ฐ๋ฌผ:** ํฌ์ฌ ํ ์ ์ํ๊ฒ ๋ฐ์คํธ๋ก์ผ์ธํํฐ์คํผ(desfuroylceftiofur)๋ก ์ ํ๋๋ฉฐ, ์ด๋ ๋ชจ์ฝ๋ฌผ๊ณผ ๋์ผํ ํจ๋ฅ์ ๊ฐ์ง๋๋ค. * **์์์ ํน์ง:** ์ผ๋ถ ์ ์ (์: Excenel RTU)๋ ์ฐฉ์ ์ฐ์์ ์ฐ์ ํ๊ธฐ ๊ธฐ๊ฐ์ด 0์ผ์ด๋ฏ๋ก ๋๋์ ์ ๋งค์ฐ ์ ๋ฆฌํ์ง๋ง, ๋์ถ ํด์ฝ ๊ธฐ๊ฐ์ ์๊ฒฉํ ์ค์ํด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Ceftiofur is a **time-dependent, bactericidal** antibiotic. * **Mechanism:** It binds to **penicillin-binding proteins (PBPs)** located inside the bacterial cell wall โ inhibits the third and final stage of bacterial cell wall synthesis โ leads to weakened cell walls, cell lysis, and bacterial death. * **Metabolism Pathway:** Parent ceftiofur is rapidly cleaved into furoic acid and **desfuroylceftiofur** (the primary active metabolite). * **Reservoir Effect:** The active metabolite is highly protein-bound, which creates a 'reservoir effect' that maintains active, therapeutic drug concentrations at the site of infection for extended periods.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Susceptible urinary tract infections ยท 2.2 mg/kg ยท SC ยท q24h ยท Not specified ยท Authorized for use in dogs in other countries where the main indication is UTI treatment.
- Sepsis/bacteraemia ยท 4.4 mg/kg ยท SC ยท q24h ยท Not specified ยท Higher (double) dose indicated to treat sepsis/bacteraemia.
- Bovine respiratory disease and acute bovine interdigital necrobacillosis ยท 1.1 to 2.2 mg/kg ยท IM/SC ยท q24h ยท 3 days (up to 5 days if needed) ยท Do not inject more than 15 mL per injection site.
- Bovine respiratory disease (BRD) only ยท 2.2 mg/kg ยท IM/SC ยท q48h ยท Days 1 and 3 ยท Do not inject more than 15 mL per injection site.
- Acute post-partum metritis ยท 2.2 mg/kg ยท IM/SC ยท q24h ยท 5 consecutive days ยท Do not inject more than 15 mL per injection site.
- Neonatal salmonellosis ยท 5 mg/kg ยท IM ยท q24h ยท 5 days
- Subclinical mastitis at time of dry off ยท Infuse one syringe (500 mg) ยท Intramammary ยท Once ยท At dry off ยท Infuse into each affected quarter.
- Clinical mastitis in lactating dairy cattle ยท Infuse one syringe (125 mg) ยท Intramammary ยท q24h ยท 2 days (up to 8 consecutive days for extended therapy) ยท Infuse into each affected quarter.
- Bacterial respiratory disease ยท 3 to 5 mg/kg ยท IM ยท q24h ยท 3 consecutive days ยท 1 mL of sterile suspension per 22 to 37 lb body weight.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Patients with a documented history of hypersensitivity to cephalosporins
- Use with caution in patients hypersensitive to other beta-lactam antibiotics (e.g., penicillins, carbapenems) due to potential cross-reactivity
์ด์๋ฐ์
- Pain on IM injection (especially in small animals)
- Hypersensitivity reactions (rashes, fever, eosinophilia, lymphadenopathy, anaphylaxis)
- Gastrointestinal distress / diarrhea
- Granulocytopenia (rare)
- Thrombocytopenia (rare)
- Injection site discoloration
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides / Nephrotoxic Drugs (e.g., amphotericin B) ยท Potential for additive nephrotoxicity. In vitro studies show synergistic antibacterial activity, but they must NOT be mixed together in the same syringe or fluid line.
- Probenecid ยท Competitively blocks the tubular secretion of most cephalosporins, thereby increasing serum levels and prolonging serum half-lives.
- Aminoglycosides ยท Synergistic antibacterial effect, but should not be mixed in the same syringe due to chemical incompatibility. ยท moderate
- Amphotericin B ยท Increased risk of nephrotoxicity. ยท major
- Loop diuretics (e.g., furosemide) ยท Increased risk of nephrotoxicity. ยท major
๋ชจ๋ํฐ๋ง
- Clinical efficacy and resolution of infection
- Weekly CBC monitoring (if used off-label in small animals)
- Renal function parameters in patients with pre-existing renal impairment
- Injection site reactions
๊ณผ์ฉ๋
Cephalosporin overdoses are generally well-tolerated and unlikely to cause significant problems other than gastrointestinal distress. However, extreme overdoses could theoretically induce hypersensitivity or hematologic abnormalities. > **Important:** Use of dosages in excess of those labeled or via unapproved routes may cause violative tissue or milk residues. Contact FARAD for assistance in determining appropriate withdrawal times if an overdose occurs in food-producing animals.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.